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Abstract
Introduction:  We  report  the  results  of  the  Portuguese  Registry  of  Hypertrophic  Cardiomyopathy,
an initiative  that  reflects  the  current  spectrum  of  cardiology  centers  throughout  the  territory
of Portugal.
Methods:  A  direct  invitation  to  participate  was  sent  to  cardiology  departments.  Baseline  and
outcome  data  were  collected.Outcome Results:  A  total  of  29  centers  participated  and  1042  patients  were  recruited.  Four  centers
recruited 49%  of  the  patients,  of  whom  59%  were  male,  and  mean  age  at  diagnosis  was  53±16
years. Hypertrophic  cardiomyopathy  (HCM)  was  identified  as  familial  in  33%.  The  major  reason
for diagnosis  was  symptoms  (53%).  HCM  was  obstructive  in  35%  of  cases  and  genetic  testingPlease  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portuguese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.repc.2017.08.005
∗ Corresponding author.
E-mail address: cardimnuno@gmail.com (N. Cardim).
1 List of participating centers and principal investigators are provided in Appendix A.
https://doi.org/10.1016/j.repc.2017.08.005
0870-2551/© 2017 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan˜a, S.L.U. All rights reserved.
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was  performed  in  51%.  Invasive  septal  reduction  therapy  was  offered  to  8%  (23%  of  obstruc-
tive patients).  Most  patients  (84%)  had  an  estimated  five-year  risk  of  sudden  death  of  <6%.
Thirteen  percent  received  an  implantable  cardioverter-defibrillator.  After  a  median  follow-up
of 3.3  years  (interquartile  range  [P25-P75]  1.3-6.5  years),  31%  were  asymptomatic.  All-cause
mortality  was  1.19%/year  and  cardiovascular  mortality  0.65%/year.  The  incidence  of  heart
failure-related  death  was  0.25%/year,  of  sudden  cardiac  death  0.22%/year  and  of  stroke-related
death 0.04%/year.  Heart  failure-related  death  plus  heart  transplantation  occurred  in  0.27%/year
and sudden  cardiac  death  plus  equivalents  occurred  in  0.53%/year.
Conclusions:  Contemporary  HCM  in  Portugal  is  characterized  by  relatively  advanced  age  at
diagnosis, and  a  high  proportion  of  invasive  treatment  of  obstructive  forms.  Long-term  mortality
is low;  heart  failure  is  the  most  common  cause  of  death  followed  by  sudden  cardiac  death.
However,  the  burden  of  morbidity  remains  considerable,  emphasizing  the  need  for  disease-
specific treatments  that  impact  the  natural  history  of  the  disease.
© 2017  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  All  rights
reserved.
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Registo  Português  de  Miocardiopatia  Hipertrófica:  resultados  globais
Resumo
Objetivo:  Apresentac¸ão  dos  resultados  do  Registo  Português  de  Miocardiopatia  Hipertrófica.
Metodologia:  Convite  direto  aos  diferentes  centros  de  cardiologia  de  Portugal,  com  análise  de
dados basais  e  de  seguimento.
Resultados:  Foram  29  os  centros  participantes  e  1042  doentes  incluídos.  Quatro  centros
incluíram 49%  dos  doentes,  59%  do  sexo  masculino,  idade  média  de  diagnóstico  53  ±  16  anos.
A doenc¸a  foi  considerada  familiar  em  33%  e  a  presenc¸a  de  sintomas  foi  a  principal  causa  de
diagnóstico (53%).  A  miocardiopatia  hipertrófica  foi  obstrutiva  em  35%.  O  estudo  genético  foi
efetuado em  51%.  Oito  por  cento  dos  doentes  fizeram  terapêutica  invasiva  de  reduc¸ão  septal
(23% dos  doentes  com  obstruc¸ão).  A  maioria  dos  doentes  (84%)  apresentava  um  risco  estimado  de
morte súbita  aos  5  anos  <  6%.  Em  13%  foi  colocado  desfibrilhador  cardioversor  implantável.  Após
um seguimento  de  3,3  anos,  intervalo  interquartil  (P25-P75)  1,3--6,5  anos,  31%  estavam  assin-
tomáticos.  A  mortalidade  total  foi  de  1,19%/ano  e  a  cardiovascular  de  0,65%/ano.  A  incidência
de morte  por  insuficiência  cardiaca  foi  de  0,25%/ano,  a  de  morte  súbita  de  0,22%/ano  e  a  de
morte por  acidente  vascular  cerebal  de  0,04%/ano.  A  mortalidade  por  insuficiência  cardíaca  e
transplante cardíaco  foi  de  0,27%/ano  e  a  de  morte  súbita  e  equivalentes  de  0,53%/ano.
Conclusões:  A  miocardiopatia  hipertrófica  em  Portugal  apresenta  idade  de  diagnóstico  elevada
e é  frequente  o  tratamento  invasivo  de  formas  obstrutivas.  A  mortalidade  é  baixa,  a  insuficiência
cardíaca  é  a  principal  causa  de  morte,  seguida  pela  morte  súbita.  A  doenc¸a  apresenta  elevada
morbilidade,  realc¸a  a  necessidade  do  desenvolvimento  de  tratamentos  específicos  com  impacto
na sua  história  natural.
©  2017  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
ICD  implantable  cardioverter-defibrillator
IVS  interventricular  septum
LVH  left  ventricular  hypertrophy
PRo-HCM  Portuguese  Registry  of  Hypertrophic
Cardiomyopathy
SCD  sudden  cardiac  death
TIA  transient  ischemic  attackList  of  abbreviations
AF  atrial  fibrillation
ASA  alcohol  septal  ablation
CMR  cardiac  magnetic  resonance
CRF  case  report  form
HCM  hypertrophic  cardiomyopathyPlease  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portu
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.rep
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The  Portuguese  Registry  of  Hypertrophic  Cardiomyopathy  
Introduction
Hypertrophic  cardiomyopathy  (HCM)  represents  an  impor-
tant  health  burden  as  a  cause  of  sudden  cardiac  death
(SCD),  heart  failure  (HF),  atrial  fibrillation  (AF)  and  stroke.
HCM  shares  many  disadvantages  of  rare  diseases,  includ-
ing  limited  recognition,  lack  of  prospective  studies  assessing
treatment,  and  little  or  delayed  access  to  advanced  treat-
ment  options  without  enjoying  their  regulatory  benefits.1--4
Randomized  clinical  trials  are  infrequent  in  HCM  and  rec-
ommendations  are  largely  based  on  expert  consensus.1--4
Additionally,  the  majority  of  studies  still  originate  from  ter-
tiary  referral  centers,  and  little  is  known  about  the  clinical
profile  and  management  of  the  disease  at  a  nationwide  level.
The  real  impact  of  genetics  and  imaging  techniques  on  ear-
lier  and  wider  recognition  of  HCM,  as  well  as  of  advanced
treatment  options  on  outcomes,  is  also  unknown.  It  is  of
paramount  importance  to  capture  these  changes  and  to
provide  answers  to  these  questions.1,2,5
Accordingly,  the  importance  of  clinical  registries  of  HCM
is  increasing,  since  they  provide  the  best  source  of  real-
world  data  in  specific  countries  and  geographical  regions.
Assuming  a  prevalence  of  1:5005 for  HCM  in  general
and  of  1:3200  for  ‘clinical  HCM’6 (patients  who  come  to
medical  attention),  the  number  of  patients  with  HCM  in  Por-
tugal  (population  about  10  million)  is  respectively  around
20  0007 and  3000.6 However,  few  studies  have  addressed  this
population.8,9 Besides  its  relevance  to  national  cardiologists,
the  Portuguese  HCM  population  represents  an  interesting
sample  because  of  the  country’s  relatively  small  size,  homo-
geneous  population  and  high  penetration  of  health  care.
The  Portuguese  Registry  of  Hypertrophic  Cardiomyopa-
thy  (PRo-HCM)  was  instituted  to  collect  information  on  the
actual  situation  of  HCM  in  Portugal.  It  specifically  assessed
epidemiological,  sociodemographic  and  clinical  data,  cur-
rent  standards  for  diagnosis,  treatment,  follow-up,  and
outcomes.  Another  aim  was  to  develop  a  reliable  source  of
information  for  health  professionals,  patients  and  families,
on  appropriateness,  effectiveness  and  quality  of  care.
Methods
Registry  design  and  methodology
The  PRo-HCM  registry  was  conceived  by  the  Working  Group
on  Myocardial  and  Pericardial  Diseases  of  the  Portuguese
Society  of  Cardiology,  directed  by  an  executive  and  a  sci-
entific  committee,  and  managed  in  the  Portuguese  National
Center  for  Data  Collection  in  Cardiology  (CNCDC).  This  study
was  formulated  and  conducted  in  compliance  with  the  prin-
ciples  of  the  declaration  of  Helsinki,  and  approved  by  the
National  Center  for  Data  Protection.  It  was  an  observa-
tional,  multicenter,  voluntary,  non-mandatory  study,  with  a
two-year  enrollment  period  (April  2013-April  2015),  retro-
spective  but  including  a  prospective  update.
A  direct  invitation  was  made  to  cardiology  departments
nationwide,  central  and  regional,  public  and  private,  aca-Please  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portu
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.repc
demic  and  non-academic,  covering  rural  and  urban,  coastal
and  inland  areas.  Additionally,  the  registry  was  advertised
in  the  Portuguese  Journal  of  Cardiology, meetings  and
newsletters.  If  the  invitation  was  accepted,  the  principal
d
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nvestigator  received  detailed  instructions,  a  center  iden-
ification  number  and  a  unique  username  and  password
o  gain  access  to  the  electronic  case  report  form  (CRF)
http://www.spc.pt/RegistosMiocardiopatia/Public/Login.
spx?ReturnUrl=%2fRegistosMiocardiopatia%2f).  The  CRF
ontained  seven  sections:  (1)  patient  identification  and
emographic/epidemiological  data;  (2)  past  history  and
aseline  clinical  data;  (3)  mortality  and  risk  stratification;
4)  diagnostic  tests;  (5)  genetic  testing,  family  screening,
nd  genetic  counseling;  (6)  treatment;  (7)  last  assess-
ent  (clinical  course,  follow-up,  and  outcomes).  In  the
iagnostic  tests  section  the  investigators  were  asked  to
nter  the  exams  performed  at  the  time  of  first  assess-
ent,  including  electrocardiogram  (ECG),  echocardiogram,
mbulatory  ECG,  exercise  test,  exercise  echocardiogram,
ardiac  magnetic  resonance  (CMR),  and  cardiac  computed
omography.
Centers  were  asked  to  include  all  patients  with  a  diagno-
is  of  HCM  followed  at  the  center  currently  or  in  the  past  (no
etrospective  time  limit),  including  those  already  deceased
t  the  time  of  enrollment.  Written  informed  consent  was
btained  from  living  patients  and  from  a  proxy  of  deceased
atients.
Inclusion  criteria  were  age  >18  years  at  the  time  of
nrollment,  and  unexplained  left  ventricular  hypertrophy
LVH):  wall  thickness  ≥15  mm  by  imaging  techniques  (in  first-
egree  relatives10 ≥14  mm  in  the  inferior  interventricular
eptum  (IVS)  or  lateral  wall  or  ≥13  mm  in  the  anterior  IVS
r  inferior  wall).
Exclusion  criteria  were  secondary  LVH  (grade  ≥2
ypertension11),  moderate  or  severe  aortic  stenosis,12 previ-
usly  diagnosed  cardiac  or  systemic  disease,  and  metabolic
r  multi-organ  syndrome  associated  with  LVH.
After  the  inclusion  period,  extra  time  was  provided  to
omplete  the  CRFs  and  to  clean  the  database.  The  final
ate  of  registry  closure  was  December  31,  2015.  CRFs  were
eviewed  to  confirm  consistency  of  data.  Whenever  nec-
ssary,  queries  were  sent  to  investigators.  In  the  event  of
epeated  patients  (same  initials,  gender  and  birth  date),  the
ne  with  the  longer  follow-up  time  was  included.
efinitions
hroughout  the  study,  most  data  are  relative  to  the  time
f  first  visit.  When  clinically  relevant,  data  at  the  time  of
iagnosis  of  HCM  are  also  shown.
Follow-up  time  was  defined  as  time  from  initial  assess-
ent  at  the  center  to  last  assessment  or  death.
Sudden  cardiac  death  (SCD)  was  defined  as  unexpected
eath  occurring  within  one  hour  of  symptom  onset  in
atients  who  had  previously  experienced  a  relatively  sta-
le  or  uneventful  clinical  course.  Resuscitation  from  cardiac
rrest  or  appropriate  implantable  cardioverter-defibrillator
ICD)  therapies  for  primary  prevention  were  considered  as
quivalents  of  SCD.
HF-related  death  was  defined  as  that  occurring  in
he  context  of  progressive  cardiac  decompensation,  withguese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
.2017.08.005
ecline  in  left  ventricular  function.13 Heart  transplantation
as  considered  as  equivalent  to  HF-related  death.
Stroke-related  deaths  in  the  setting  of  paroxysmal,  per-
istent  or  permanent  AF  were  classified  as  AF-stroke  related
ARTICLE IN PRESS+ModelREPC-1139; No. of Pages 10
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Figure  1  Participating  centers  in  the  Pro-HCM  registry:  distribution  by  regions  and  by  center.  Left:  participating  centers  (n=29);
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cop right:  distribution  of  the  1042  patients  by  regions  of  Portu
he central  region  of  Portugal  the  lowest;  bottom  right:  note  th
eaths.  Stroke-related  deaths  in  the  absence  of  documented
F  were  not  included  in  this  group.
Thromboembolic  events,  defined  as  stroke,  transient
schemic  attack  (TIA)  or  systemic  peripheral  embolism,  were
ecorded.14
The  classification  of  identified  genetic  variants  was
ssigned  to  the  investigators,  as  pathogenic/probably
athogenic,  of  unknown  significance  or  benign/probably
enign,  according  to  current  knowledge  of  their
athogenicity,15,16 as  provided  by  genetic  laboratories
these  data  were  not  centrally  reviewed  or  corrected  by  the
oordinators  of  the  registry).  A  genetic  study  was  defined
s  negative  if  no  pathogenic/probably  pathogenic  mutation
as  detected  and  as  in  progress  if  no  result  was  provided  at
nclusion.
tatistical  analysis
ontinuous  variables  were  expressed  as  mean  and  standard
eviation  or  as  median  and  interquartile  range  (IQR)  (P25-
75).  Categorical  variables  were  given  as  total  number  and
ercentages.  Chi-square  or  Fisher  tests  were  used  for  com-
arisons  of  categorical  variables  and  Student’s  t  tests  for
ontinuous  variables.  Survival  was  assessed  by  Cox  propor-
ional  hazard  regression.  Survival  curves  were  constructedPlease  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portu
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.rep
ccording  to  the  Kaplan-Meier  method,  and  comparisons
ere  performed  using  the  log-rank  test.  All  p-values  were
wo-sided  and  considered  significant  when  <0.05.  All  analy-
es  were  performed  using  SPSS  19.0
®
.
D
T
rhe  Lisbon  region  included  the  highest  number  of  patients  and
terogeneity  in  terms  of  patients  enrolled  per  center.
esults
f  the  62  institutions  contacted,  37  accepted,  and  the  final
umber  of  participating  centers  was  29  (Figure  1).  The  total
umber  of  patients  was  1042.  Figures  were  compared  with
ther  national  registries17,18 (Table  1).
aseline  assessment
lmost  half  of  the  patients  (n=514,  49%)  came  from  the
our  major  centers  with  specific  interest  in  HCM  (the  other
5  centers  enrolled  528  patients,  51%)  (Figure  1).  The  Lisbon
egion  included  the  largest  number,  followed  by  the  North
egion,  the  South  and  Islands,  and  the  Central  region.  Of  the
9  centers,  only  three  included  more  than  100  patients  and
ight  more  than  50  patients.  Twenty-one  centers  included
ewer  than  50  patients  each,  13  centers  fewer  than  10  and
ix  centers  fewer  than  five.
The  patient  cohort  showed  a  slight  preponderance  of
ales.  Mean  age  at  diagnosis  was  53±16  years  and  more
han  one  quarter  were  diagnosed  over  the  age  of  65  years.
he  disease  was  classified  as  familial  in  one  third.  At  first
onsultation  most  patients  were  symptomatic19 (Table  2).guese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
c.2017.08.005
iagnostic  tests
he  ECG  was  abnormal  in  964  individuals  (93%).  AF  was
ecorded  in  117  (11%).
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Table  1  Comparison  between  populations  of  national  registries  of  hypertrophic  cardiomyopathy.
Portuguese  registry  (PRo-HCM)  Italian  registry17 French  registry18
Registry  period  2013-2015  2000-2002  2005-2015
Country population  10  million  50  million  66  million
Patients in  registry 1042  1677  1401
Estimated prevalence  of  HCM  based  on  the  CARDIA  study:  1:5005
HCM  patients 20  000 100  000 132  000
Patients included  in  registry  5%  2%  1%
Estimated prevalence  of  ‘clinical’  HCM:  1:  32006
Patients  with  ‘clinical’  HCM  3125  16  000  18  750
Patients included  in  registry  33%  10%  7%
HCM: hypertrophic cardiomyopathy.
Table  2  Summary  of  baseline  characteristics  and  diagnos-
tic tests.
n  %
HCM  patients 1042
Male/female  613/429  59/41
Age at  diagnosis 53±16  (9-88)
Diagnosis  >50  years 605  58
Diagnosis  >65  years 281  27
Familial/sporadic  347/559  33/54
Non-obstructive  HCM 613  59
Obstructive  HCM 365  35
Reason for  diagnosis
Symptoms  551  53
Incidental  319  31
Family screening  129  12
Symptoms  at  first  consultation
Asymptomatic  311  30
Symptomatic  715  69
Dyspnea  328  32
Angina 241  23
Palpitations  189  18
Syncope  95  9
NYHA I/II/III/IV  146/792/94/10  14/76/9/1
Imaging  method  of  diagnosis
Echocardiography  932  89
CMR/CCT  110  11
Holter 867  83
Exercise  test  437  42
Exercise  echocardiography  175  17
CMR 475  46
CA 122  12
EMB 12  1
Genetic  test  528  51
CA: cardiac angiography; CCT: cardiac computed tomography;
CMR: cardiac magnetic resonance; EMB: endomyocardial biopsy;
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Echocardiographic  assessment  at  enrollment  showed  that
HCM  was  non-obstructive  (instantaneous  peak  Doppler  intra-
ventricular  pressure  gradient  <30  mmHg)  in  613  (59%  of
patients)  and  obstructive  in  365  (35%)  (Table  2).  Of  these,
(
f
u23  (88%)  had  obstruction  at  rest  and  42  (12%)  had  exercise-
nduced  obstruction  only,  during  exercise  echocardiography.
bstruction  was  at  the  left  ventricular  outflow  tract  in  89%.
n  apical  aneurysm  was  present  in  23  patients  (2%).
On  ambulatory  Holter  ECG  monitoring,  AF  was  present  in
18  patients  (11%).  An  exercise  test  was  carried  out  in  less
han  half  of  the  population  and  exercise  echocardiography
n  approximately  one  fifth  (Table  2).
CMR  was  performed  in  almost  half  of  the  cohort.  Its  incre-
ental  value  over  echocardiography  was  the  assessment  of
brosis  (59%),  diagnosis  in  false-negative  echocardiograms
6%)  and  detection  of  massive  LVH  (4%).
isk  stratification  for  sudden  cardiac  death
t baseline  (at  the  time  of  the  first  visit)
ased  on  the  American  Heart  Association  model  for  SCD2,20
Supplementary  Table  1),  half  of  the  patients  had  no  risk  fac-
ors,  one  third  had  one  risk  factor  and  15%  more  than  one
isk  factor.  Our  data  also  showed  that  according  to  the  Euro-
ean  Society  of  Cardiology  SCD  risk  score,1,21 the  majority
f  patients  had  a  five-year  risk  lower  than  4%.
enetic  testing
n  total,  51%  of  the  patients  had  undergone  genetic  testing
nd  in  40%  of  these  a  pathogenic/probably  pathogenic  muta-
ion  was  found  (Table  3).  In  this  group,  when  the  causative
ene  mutation  was  reported,  the  two  most  frequent  genes
ere  MYBPC3  and  MYH7.
reatment
ost  patients  (n=909;  87%)  received  medical  treatment
Table  4).  Septal  reduction  therapy  was  performed  in  8%  of
he  cohort,  23%  of  the  obstructive  group.  Cardiac  surgery
as  performed  2.6  times  more  frequently  than  ASA.  Surgery
as  performed  in  11  centers  (of  these,  only  two  performed
ore  than  10  surgeries).  ASA  was  performed  in  four  centersguese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
.2017.08.005
only  one  reached  10  procedures).
An  ICD  was  implanted  in  13%  of  the  population,  mainly
or  primary  prevention.  A  pacemaker  was  implanted  in  9%,
sually  for  conduction  disorders.
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Table  3  Results  of  genetic  testing.15,16
n  %
HCM  patients  tested  528  51
Positive  210  40
VUS 40  8
Pathogenic/probably  pathogenic  mutationa 210
MYBPC3  99  49
MYH7 56  28
TNNT2 25  12
TNNI3 10  5
TPM1 8  4
CRSP3 8  4
MYL3 2  1
MYL2 1  0.5
CRSP3: muscle LIM protein; HCM: hypertrophic cardiomyopa-
thy; MYBPC3: cardiac myosin-binding protein C; MYH7: myosin
heavy chain; MYL2: regulatory myosin light chain; MYL3: essen-
tial myosin light chain; TNNI3: cardiac troponin I; TNNT2: cardiac
troponin T; TPM1: tropomyosin; VUS: variants of unknown signif-
icance.
a Raw data derived from CRF data, inserted by the investiga-
tors as reported by the genetic laboratory and not confirmed by
the coordinators of the registry, including the attributed classi-
fication of ‘pathogenic/probably pathogenic mutation’.
Table  4  Treatment  in  the  PRo-HCM  registry.
n  %
Beta-blockers  768  74
CCBs 262  25
Disopyramide  19  2
Amiodarone  151  15
Anticoagulants  276  27
VKAs 208  75
NOACs 60  22
ACEIs 226  22
ARBs 178  17
Diuretics  252  24
Nitrates  24  2
ASA 23  2
Surgery 61  6
ICD 140  13
Primary  prevention  123  88
Secondary  prevention  15  11
Pacemaker  92  9
Bradyarrhythmia  64  70
Gradient  reduction  19  21
ACEIs: angiotensin-converting enzyme inhibitors; ARBs:
angiotensin receptor blockers; ASA: alcohol septal ablation;
CCBs: calcium channel blockers; ICD: implantable cardioverter
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ean  follow-up  was  5.3±6.1  years,  median  3.3  years  (IQR
P25-P75]  1.3-6.5  years).  At  last  assessment,  most  patients
ere  symptomatic  (Figure  2),  usually  with  mild  to  moderate
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ymptoms.  A  small  number  (n=42,  4%)  developed  systolic
ysfunction.
All-cause  mortality  was  6.2%  (Table  5).  Cardiovascular
ortality  was  3.4%,  most  frequently  due  to  HF,  followed  by
CD  and  by  stroke-related  death.
In  univariate  analysis,  16  of  the  predefined  variables
ere  significantly  related  to  mortality.  Multivariate  analysis
howed  four  major  risk  indicators  of  cardiovascular  mor-
ality:  late  diagnosis  (>60  years),  family  history  of  SCD,
rogressive  systolic  dysfunction  and  obstructive  HCM  (Sup-
lementary  Table  2).
Of  the  12  patients  with  SCD,  seven  were  between  40
nd  65  years  old,  three  were  older  than  65,  and  only  two
ere  aged  under  40  years.  In  a  number  of  patients  SCD
as  aborted  by  appropriate  ICD  shocks  in  the  setting  of
rimary  prevention  or  documented  successful  in-  and/or
ut-of-hospital  resuscitation.  Therefore,  actual  plus  aborted
CD  occurred  in  29  patients.
The  incidence  of  all-cause  and  cardiovascular  mortality
as  1.19%/year  and  0.65%/year,  respectively;  the  incidence
f  HF-related  death  was  higher  than  that  of  SCD,  and  the  lat-
er  was  higher  than  that  of  stroke.  However,  the  incidence  of
CD  death  plus  equivalents  was  higher  than  the  incidence  of
F  death,  with  or  without  equivalents  (Table  5  and  Figure  3).
Thromboembolic  events  occurred  in  65  patients  (6%)
stroke  n=52,  TIA  n=11,  peripheral  embolism  n=2).  Of  these,
alf  had  documented  AF.
Compared  with  low-volume  centers  (<15  patients
ncluded,  n=16),  high-volume  (>100  patients,  n=3)  centers
ad  younger  patients  and  more  familial  HCM  and  performed
ore  genetic  testing,  family  screening  and  exclusion  of  phe-
ocopies  (Supplementary  Table  3).  Additionally,  despite  the
igher  number  of  diagnostic  tests  and  of  drug  prescriptions
f  high-volume  centers,  no  major  differences  in  outcomes
ere  found.
iscussion
he  PRo-HCM  registry  provides  a  detailed  contemporary
ssessment  of  the  clinical  profile,  management  strategies
nd  outcomes  of  HCM  in  Portugal.  While  most  data  are
onsistent  with  the  existing  literature,17,18,22 the  present
ndings  show  elements  of  novelty  and  some  differences
rom  the  guidelines.1,2 Our  results  are  important  at  both
ational  and  international  level,  as  several  countries,  world-
ide,  may  face  similar  conditions  in  the  management  of  the
isease.
pidemiological  and  sociodemographic  data
he  total  number  of  patients  included  represents  about  5%
f  the  estimated  prevalence  in  Portugal,5,7 but  up  to  one
hird  of  the  Portuguese  population  with  ‘clinical’  HCM.6
ccordingly,  this  is,  to  our  knowledge,  the  most  compre-
ensive  national  HCM  registry  published.17,18,22 This  national
ffort  provides  credibility  to  our  data  as  representative  of
he  real  Portuguese  scenario.  The  distribution  of  patientsguese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
c.2017.08.005
etween  referral  and  community-based  centers  (four  cen-
ers  included  half  of  the  patients  and  25  centers  the  other
alf)  shows  that  a  significant  number  of  patients  are  fol-
owed  in  non-referral  centers.  Of  note,  however,  was  the
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Figure  2  Follow-up  data:  symptoms  at  last  assessment.  At  the  la
majority had  mild  to  moderate  symptoms  (right).
Table  5  Mortality  in  the  PRo-HCM  registry.
n  Mortality  rate
Total  mortality  65  1.19%/year
CV mortality  36  0.65%/year
HF-related  death  14  0.25%/year
SCD 12  0.22%/year
Stroke-related  death  2  0.04%/year
Other 8  0.15%/year
SCD equivalents  17  0.31%/year
SCD death  plus  equivalents  29  0.53%/year
HF equivalents  1  0.02%/year
HF death  plus  equivalents 15  0.27%/year
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low  proportion  of  reported  familial  HCM,  probably  reflecting
a  low  rate  of  systematic  family  screening  programs  and/or
a  referral  center  bias  in  another  registry.22
Baseline  assessment
Over  a  decade  since  the  publication  of  another  national
registry,17 the  clinical  spectrum  of  HCM  appears  very  sim-
ilar,  suggesting  that  its  clinical  profile  is  not  undergoing
major  changes  in  the  Western  world.  The  major  difference
is  the  older  age  at  diagnosis,  with  more  than  one  fourth  of
patients  diagnosed  over  the  age  of  65  years.  This  finding
may  reflect  delayed  disease  penetrance,  lack  of  systematic
family  screening,  and  --  potentially  --  an  increased  diagnos-
tic  yield  in  older  patients.1,2 By  contrast,  the  association
found  in  our  cohort  of  a  low  rate  of  familial  HCM,  later  age
of  presentation,  and  low  risk  profile,  may  more  closely  mir-
ror  the  real-world  disease  scenario,  reflecting  the  inclusion
of  these  unselected  lower-risk  HCM  patients  in  the  cohort.
Recent  reports  have  in  fact  identified  a  lower-risk  cohort  of
HCM  patients,  with  later  onset  and  lower  rate  of  familialPlease  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portu
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.repc
disease,23,24 which  may  explain  our  findings.
The  proportion  of  obstructive  forms  in  our  cohort,  about
one  third,  basically  reflects  patients  with  obstruction  at
rest,  and  is  consistent  with  the  existing  literature  for  resting
T
I
ost  assessment  most  patients  were  symptomatic  (left),  and  the
bstruction.1,2 Accordingly,  due  to  the  low  rate  of  exercise
chocardiography  performed,25 many  patients  with  labile
bstruction  were  probably  not  detected  and  were  classified
s  non-obstructive,  which  at  first  sight  suggests  a  deviation
rom  the  guidelines.  However,  as  the  recommendations1,2
or  the  use  of  exercise  echocardiography  in  non-obstructive
CM  at  rest  are  relatively  recent,  some  of  these  patients,
ssessed  earlier,  have  not  undergone  exercise  echocar-
iography  and  were  diagnosed  as  non-obstructive  in  this
bservational  study.
iagnostic  tests  and  sudden  cardiac  death  risk
tratification at  baseline
ur  data  show  a  relatively  limited  penetration  of  CMR,
espite  the  evidence  of  its  incremental  value.1--4 These
esults  reflect  its  high  costs,  limited  availability,  and
elatively  recent  introduction  in  clinical  practice.1--4
y  contrast,  despite  the  factors  that  limit  the  dissemina-
ion  of  genetic  testing1,2 (price,  lack  of  co-payment,  low
vailability),  half  of  the  patients  underwent  genetic  study,
hich  in  many  cases  is  already  part  of  routine  practice.26
he  proportion  of  tests  in  which  a  variant  was  found15,16,27,28
nd  the  relative  prevalence  of  the  disease-causing  genes  is
ostly  similar  to  what  has  been  described.1,2,15,16,27,28 How-
ver,  according  to  the  results  provided  by  the  investigators,
n  unexpectedly  high  prevalence  of  pathogenic/probably
athogenic  mutations15,16,27,28 was  found  in  the  TPM1  and
SRP3  genes.17 These  results  should  be  interpreted  with
aution,  because  they  are  derived  from  CRF  raw  data  that
ere  not  centrally  reviewed  or  corrected  by  the  PRo-HCM
oordinators.
Both  of  the  contemporary  models  for  SCD  risk1,2,20,21 show
hat  our  cohort  was,  at  baseline,  a  low-risk  population  for
CD,  which  partially  explains  the  low  rate  of  SCD  and  of  ICD
mplantations.guese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
.2017.08.005
reatment
nvasive  septal  reduction  was  offered  to  almost  one  fourth
f  obstructive  patients,  including  those  who  were  mildly
ARTICLE IN PRESS+ModelREPC-1139; No. of Pages 10
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Figure  3  Kaplan-Meier  estimates  of  the  cumulative  hazard  function  for  mortality  during  follow-up.  Left:  cumulative  hazard
function for  mortality;  right:  cumulative  hazard  function  for  mortality,  including  sudden  cardiac  death  and  heart  failure  equivalents.
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ymptomatic.  Although  it  cannot  be  excluded  that  this  rate
s  biased  by  the  low  number  of  patients  detected  with  labile
bstruction,  it  probably  also  results  from  knowledge  of  the
dverse  long-term  effects  of  obstruction,  as  well  as  from
he  safety  of  invasive  procedures,  which  may  impact  future
CM  guidelines.
Of  note,  the  number  of  surgical  myectomies  was  much
igher  than  the  number  of  ASA  procedures,  which  is  partially
xplained  by  the  late  introduction  of  the  latter  in  Portugal
2009).29 The  fact  that  the  two  procedures  were  performed
n  different  centers  deserves  reflection,  taking  into  account
he  known  effect  of  expertise  on  results.1,2
Finally,  fewer  than  15%  of  patients  received  an  ICD  during
ollow-up,  reflecting  the  low  risk  profile  of  our  non-selected
opulation.
ollow-up,  morbidity  and  mortality
verall,  our  data  suggest  that  in  Portugal,  in  the  era  of
etter  diagnostic  and  therapeutic  techniques,  HCM  has  low
ortality  but  high  morbidity.
Additionally,  despite  greater  use  of  diagnostic  tests  and
ifferences  in  medical  treatment,  outcomes  of  high-volume
enters  are  similar  to  those  of  low-volume  centers,  calling
nto  question  the  value  of  HCM  centers  and  of  the  ‘hub  and
poke’  model.7
Outcome  data  show  that  the  SCD  rate  in  HCM  patients  inPlease  cite  this  article  in  press  as:  Cardim  N,  et  al.  The  Portu
results.  Rev  Port  Cardiol.  2018.  https://doi.org/10.1016/j.rep
ortugal  is  very  low.  Even  though  this  finding  may  be  partially
xplained  by  lives  saved  by  successful  resuscitation  and  ICD
mplantation,  the  incidence  of  SCD  is  still  low  after  including
hese  SCD  equivalents  in  the  SCD  rate.  As  a  consequence  of
i
o
dlure  mortality;  HF+Equiv:  heart  failure  mortality+  equivalents;
ty;  SCD+Equiv:  sudden  cardiac  death  mortality  +  equivalents.
he  efficacy  of  these  preventive  measures,  HF  has  become
he  leading  cause  of  death  in  HCM  patients  in  Portugal.
Our  figures  are  in  overall  agreement  with  those  from
ther  groups,30 showing  that  overall  mortality  in  treated
CM  in  Portugal  is  1.19%,  similar  to  that  of  the  general
ortuguese  population  (around  1.1%  year).31 Importantly,
t  follow-up  most  patients  were  symptomatic,  confirming
hat  disease  morbidity  represents  a  significant  burden  to
atients,  health  care  services  and  providers.  Accordingly,
he  ‘‘contemporary  treatable  disease’’30 has  became,  at
east  in  Portugal,  a  ‘‘contemporary  chronic  treatable  dis-
ase’’  in  which,  side  by  side  with  ICDs,  the  role  of  chronic
edical  treatment  is  increasing.
imitations
espite  their  inherent  limitations,  registries  provide  realis-
ic  geographical  data  on  disease  course  and  management.
The  inclusion  of  mostly  symptomatic  patients  with
dvanced,  established  disease  (mainly  included  by  HCM
eferral  centers)  is  a  limitation  of  this  registry,  providing
 biased  view  of  the  disease  (selection  bias,  a  common  lim-
tation  of  many  HCM  studies).
Additionally,  disease-related  mortality  is  underesti-
ated,  as  patients  who  died  before  diagnosis  were  notguese  Registry  of  Hypertrophic  Cardiomyopathy:  Overall
c.2017.08.005
ncluded.  This  survival  bias  partially  explains  the  low  rate
f  events,  especially  the  low  rate  of  SCD.
Children  were  excluded  because  of  important  clinical
ifferences.1,2
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Future  directions
The  identification,  at  a  national  level,  of  discrepancies
between  our  data  and  the  guidelines  is  an  important  finding,
warranting  a  national  effort  to  correct  them  (for  instance
to  include  exercise  echocardiography  as  a  standard  initial
assessment  of  non-obstructive  HCM  at  rest,  to  better  detect
labile  obstruction).
Because  of  the  large  volume  of  data,  we  were
unable  to  cover  some  important  topics  in  depth.  Accord-
ingly,  further  work  will  be  directed  at  comparisons
between  subgroups,  addressing  family  screening,  genetic
testing  (including  founder  effects,  differences  in  pheno-
type  between  genes,  and  analysis  of  specific  mutations
considered  as  pathogenic/probably  pathogenic  by  the
investigators),  awareness  of  phenocopies  (for  instance
Fabry  disease),  and  detailed  assessment  of  clinical  HCM
profiles.
Conclusions
The  PRo-HCM  registry  provides  comprehensive  data  on  the
management  of  HCM  in  Portugal  in  the  era  of  genetics,  CMR,
ICDs  and  ASA,  and  indicates  the  need  for  better  access  to
resources  and  some  deviations  from  guidelines.
Contemporary  HCM  in  Portugal  is  characterized  by  rel-
atively  advanced  age  at  diagnosis,  and  a  high  proportion
of  invasive  treatment  of  obstructive  forms  at  rest.  Long-
term  mortality  is  low,  and  HF  is  the  most  common  cause
of  death  followed  by  SCD  (excluding  equivalents).  However,
morbidity  remains  considerable,  emphasizing  the  need  for
disease-specific  treatments  that  impact  the  natural  history
of  the  disease.
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orreia;  CUF  Infante  Santo  Hospital:  Pedro  Matos;  Hospital
eatriz  Ângelo:  Luís  Sargento;  Hospital  da  Luz  Lisboa:  Nuno
ardim;  Hospital  das  Forc¸as  Armadas:  Sara  Ferreira;  Hospi-
al  de  Braga:  Nuno  Salomé:  Hospital  de  Santa  Maria  Maior  de
arcelos  -  Servic¸o Cardiologia:  Alexandra  Sousa;  Hospital  de
anto  Espírito  de  Angra  do  Heroísmo:  Rute  Couto;  Hospital
e  São  João:  Elisabete  Martins;  Hospital  do  Espírito  Santo:
gostinho  Caeiro;  Hospital  Garcia  de  Orta:  Luís  Rocha  Lopes;
ospital  Prof.  Doutor  Fernando  Fonseca:  Francisco  Madeira;
ospital  SAMS:  Berta  Carola;  HPP  Hospital  de  Cascais  -  Hos-
ital  Dr.  José  de  Almeida:  Gonc¸alo Proenc¸a; Unidade  Local
e  Saúde  da  Guarda  - Hospital  Sousa  Martins:  Maria  Cristina
amboa.
ppendix B. Supplementary material
upplementary  material  associated  with  this  article  can
e  found  in  the  online  version  at  doi:10.1016/j.repc.
017.08.005.
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